{"id":1940,"company":{"country":"US","currency":"USD","exchange":"NASDAQ NMS - GLOBAL MARKET","ipo":"2021-03-19","marketCap":41.066,"name":"Instil Bio Inc","phone":"19724993350.0","outstanding":130.08,"symbol":"TIL","website":"https://instilbio.com/","industry":"Biotechnology"},"price":6.4475,"year":2023,"month":12,"day":14,"weekday":"Thursday","title":"Historical Stock Splits and Corporate Actions of Instil Bio Inc","date":"2023-12-14","url":"/posts/2023/12/14/TIL","content":[{"section":"2019","text":"No significant stock splits or corporate actions reported."},{"section":"2018","text":"No significant stock splits or corporate actions reported."},{"section":"2017","text":"No significant stock splits or corporate actions reported."},{"section":"2016","text":"No significant stock splits or corporate actions reported."},{"section":"2015","text":"No significant stock splits or corporate actions reported."},{"section":"2014","text":"No significant stock splits or corporate actions reported."},{"section":"2013","text":"No significant stock splits or corporate actions reported."},{"section":"2012","text":"No significant stock splits or corporate actions reported."}],"tags":["CrossOver200","Long","Biotechnology"],"news":[{"category":"company","date":1702461300,"headline":"TIL Stock Earnings: Instil Bio Beats EPS for Q2 2023","id":124497709,"image":"","symbol":"TIL","publisher":"InvestorPlace","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3255130886"},{"category":"company","date":1702461300,"headline":"TIL Stock Earnings: Instil Bio Misses EPS for Q3 2023","id":124497708,"image":"","symbol":"TIL","publisher":"InvestorPlace","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3255130888"},{"category":"company","date":1702461300,"headline":"TIL Stock Earnings: Instil Bio Misses EPS for Q1 2023","id":124497707,"image":"","symbol":"TIL","publisher":"InvestorPlace","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3255130883"},{"category":"company","date":1701931800,"headline":"Instill Bio trading halted, news pending","id":124389019,"image":"","symbol":"TIL","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3246899525"},{"category":"company","date":1701813600,"headline":"Instil Bio Announces Effective Date of 1-for-20 Reverse Stock Split","id":124319145,"image":"https://s.yimg.com/ny/api/res/1.2/nTgCjRLf9r_FeST_.Zw7cw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD00NjY-/https://media.zenfs.com/en/globenewswire.com/7dde9e6eec6deb8cc2581216054a6f3a","symbol":"TIL","publisher":"Yahoo","summary":"DALLAS, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil” or the “Company”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today announced that a 1-for-20 reverse stock split of its outstanding shares of common stock will be effective as of 5:00 p.m. Eastern Time on Thursday, December 7, 2023. The Company’s common stock will begin trading on a reverse stock spli","url":"https://finance.yahoo.com/news/instil-bio-announces-effective-date-220000486.html"},{"category":"company","date":1701797580,"headline":"Instil Bio Shares Fall 7% After Reverse Split News","id":124421417,"image":"https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png","symbol":"TIL","publisher":"MarketWatch","summary":"By Stephen Nakrosis Shares of Instil Bio were trading below previous 52-week lows in Tuesday's after-hours market, following news the biopharmaceutical...","url":"https://www.marketwatch.com/story/instil-bio-shares-fall-7-after-reverse-split-news-97b5e162"}]}